GADOLINIUM USE FOR RESEARCH SUBJECTS

Category: Magnetic Resonance Imaging (MRI) Safety
Procedure #: MR.SOP.04
Applies to: Investigators, study personnel, Medical College of Wisconsin (MCW) staff

PURPOSE:

In response to reported cases of individuals acquiring Nephrogenic Systemic Fibrosis (NSF) due to administration of Gadolinium-based contrast agents (GBCAs), the American College of Radiology (ACR) updated its guidelines in May 2017 and the FDA issued a warning in September 2017 for GBCAs regarding gadolinium retention in certain organs and tissues. The FDA Medication Guide was subsequently updated in May 2018. The purpose of this document is to describe the MCW Research MRI Safety Committee recommendations with regards to the use of GBCA in research subjects.

PROCEDURES:

The MCW Research MRI Safety Committee recommends that the current practices that Froedtert Hospital uses for clinical MRI scans be applied to research scans. These practices can be reviewed by searching for “MR 0390 Contrast and Medication Management” on the Froedtert Hospital intranet site.

Approval Date: 08/15/2019
Effective Date: 08/15/2019
Review Date: 08/15/2019
Revision History: 09/12/2007, 01/10/2013, 11/3/2014, 05/17/2018, 08/15/2019
Approved By: Research MRI Safety Committee